Healthcare Industry News: radiosurgery
News Release - May 18, 2010
Accuray Hires General Manager for the EIMEA RegionSUNNYVALE, Calif., May 18 (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq:ARAY ), a global leader in the field of radiosurgery, announced today that Vittorio Puppo, M.D., has joined Accuray as General Manager of the EIMEA (Europe India Middle East and Africa) region, effective May 17, 2010.
Prior to joining Accuray, Puppo worked for Covidien, a healthcare device and supply company, where he served most recently as the EMEA President of the Surgical Devices division, and as EMEA President of the Imaging division. Prior to joining Covidien, Puppo worked in a variety of roles at Amersham Health, an imaging diagnostics and therapy company, which was later acquired by GE Healthcare. During his career Puppo has worked and lived in Italy, UK, France and Switzerland.
"Vittorio Puppo's established experience in the healthcare industry throughout Europe will help us lead teams to continue to grow market share throughout this region," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "We are very excited to have him on board and see this as a major step toward the success of our regional business model and worldwide expansion of the CyberKnife System."
Puppo will report to Accuray's president and chief executive officer, and will be fully responsible for leading finance, sales, service and marketing for the EIMEA region.
Presently there are 27 CyberKnife Systems installed throughout EIMEA, making it the second largest installed base of CyberKnife Systems after the United States.
About the CyberKnife® Robotic radiosurgery System
The CyberKnife Robotic radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq:ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 80,000 treatments worldwide and currently 196 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to qualitative management experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on May 6, 2010, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China